---
title: "Artiva Biotherapeutics to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290603408.md"
description: "Artiva Biotherapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Management is scheduled to hold a fireside chat at 3:30 p.m. EDT."
datetime: "2026-06-23T20:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290603408.md)
  - [en](https://longbridge.com/en/news/290603408.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290603408.md)
generator: "portal-rs"
---

# Artiva Biotherapeutics to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat

-   Artiva Biotherapeutics will join the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. \* Management is scheduled for a fireside chat at 3:30 p.m. EDT. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606231605PRIMZONEFULLFEED9751303) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARTV.US](https://longbridge.com/en/quote/ARTV.US.md)

## Related News & Research

- [Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 8,222 shares for $98,730.32](https://longbridge.com/en/news/297569079.md)
- [BlackRock Inc. Takes $6.74 Million Position in Artiva Biotherapeutics, Inc. $ARTV](https://longbridge.com/en/news/298099838.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [Regeneron announces Q3 2026 dividend of R$ 0.05 per unit](https://longbridge.com/en/news/297814808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**